Safety of Roxadustat in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis.

In long-term treatment, the risk of SAEs, hypertension, and diarrhea was notable, while the risk of hyperkalemia remained borderline significant. 5.

also in 6,822 other papers

Notably, the subgroup of patients without dialysis and with treatment > 30 weeks had a near-significant increased risk of hyperkalemia compared to placebo (pooled OR = 1.28; 95% CI: 0.99–1.65; I 2 = 0.0%) but not compared to ESAs ( Figure 13 c).

also in 1,659 other papers

Similarly, when we analyzed the data according to the duration of Roxadustat treatment, an increased risk was observed with both longer and shorter treatments than 30 weeks, but this increase did not reach statistical significance in either case ( Figure 13 a,b).

also in 75,868 other papers

Subgroup analysis by dialysis or non-dialysis status indicated that the risk of SAEs was statistically significant in the anemic CKD patient group not receiving dialysis (pooled OR = 1.15; 95% CI: 1.01–1.30; I 2 = 0.0%) ( Figure 4 a), while it was marginally non-significant in the dialysis patient group (pooled OR = 1.12; 95% CI: 0.99–1.26; I 2 = 0.0%) ( Figure 4 a).

also in 988 other papers